WORCESTER, Mass., Jan. 8, 2010 (GLOBE NEWSWIRE) -- For most people when it comes to Generex (Nasdaq:GNBT), the focus is squarely on its flagship buccal insulin spray product, Generex Oral-lyn(TM), and its application in the diabetes arena. That focus is understandable as there is no doubt that, in order for the Company to achieve near-term large scale commercial success, Generex Oral-lyn(TM) must lead the way. I also believe that in addition to the other promising drug programs such as cancer vaccines and synthetic influenza vaccines, what is often overlooked when people evaluate Generex is that the success of Generex Oral-lyn(TM) may well validate Generex’s proprietary RapidMist(TM) drug delivery method and open up a myriad of lucrative opportunities for the Company.
